
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
Wed 14 May 25, 08:01 PMBionano Genomics (BNGO) Q4 2024 Earnings Call Transcript
Tue 01 Apr 25, 12:30 AMBionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
Mon 31 Mar 25, 08:01 PMBionano Announces Effective Date of Reverse Stock Split
Wed 22 Jan 25, 09:05 PMBionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
Wed 09 Oct 24, 09:18 PM3 Contrarian Investments to Make Now for Massive Upside Potential
Thu 25 Apr 24, 05:10 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -26.32800M | -111.98400M | -232.43100M | -130.71200M | -78.15200M |
| Minority interest | - | - | - | - | - |
| Net income | -26.39500M | -112.01700M | -232.49300M | -132.59600M | -72.43500M |
| Selling general administrative | 35.15M | 51.85M | 93.50M | 88.60M | 58.49M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 6.26M | 0.38M | 9.57M | 5.95M | 3.87M |
| Reconciled depreciation | 9.73M | 14.23M | 13.91M | 9.84M | 3.37M |
| Ebit | -33.33900M | -111.69500M | -227.31200M | -131.69800M | -77.10100M |
| Ebitda | -23.60800M | -97.46900M | -213.60400M | -130.41400M | -76.92400M |
| Depreciation and amortization | 9.73M | 14.23M | 13.71M | 1.28M | 0.18M |
| Non operating income net other | - | - | - | -0.22300M | -0.36000M |
| Operating income | -33.33900M | -103.98300M | -215.24500M | -131.69800M | -77.10100M |
| Other operating expenses | 61.85M | 134.76M | 251.36M | 159.50M | 95.08M |
| Interest expense | 0.30M | 0.29M | 5.12M | 0.30M | 0.93M |
| Tax provision | 0.07M | 0.03M | 0.06M | 1.88M | -5.71700M |
| Interest income | 4.89M | 2.10M | 3.31M | 1.51M | 0.24M |
| Net interest income | 4.60M | -1.82500M | -1.80800M | 1.21M | -0.69100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.07M | 0.03M | 0.06M | 1.88M | -5.71700M |
| Total revenue | 28.51M | 30.78M | 36.12M | 27.80M | 17.98M |
| Total operating expenses | 39.60M | 104.36M | 224.81M | 137.64M | 80.97M |
| Cost of revenue | 22.25M | 30.40M | 26.55M | 21.86M | 14.11M |
| Total other income expense net | 7.01M | -8.00100M | -17.18600M | 0.99M | -1.05100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -26.39500M | -112.01700M | -232.49300M | -132.59600M | -72.43500M |
| Net income applicable to common shares | - | - | - | -132.59600M | -72.43500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 73.58M | 76.67M | 214.40M | 307.50M | 377.10M |
| Intangible assets | 4.34M | 9.71M | 33.97M | 41.14M | 26.84M |
| Earning assets | - | - | - | - | - |
| Other current assets | 21.48M | 14.12M | 5.68M | 7.33M | 4.48M |
| Total liab | 29.16M | 41.30M | 118.25M | 58.10M | 39.98M |
| Total stockholder equity | 44.42M | 35.38M | 96.16M | 249.40M | 337.12M |
| Deferred long term liab | - | - | - | 0.13M | 0.15M |
| Other current liab | 16.41M | 4.91M | 8.09M | 19.93M | 9.69M |
| Common stock | 0.00100M | - | 0.00500M | 0.03M | 0.03M |
| Capital stock | 0.00100M | 0.00000M | 0.00500M | 0.03M | 0.03M |
| Retained earnings | -719.62000M | -693.22500M | -581.20800M | -348.71500M | -216.11900M |
| Other liab | - | - | - | 13.10M | 9.21M |
| Good will | - | - | 0.00000M | 77.29M | 56.16M |
| Other assets | - | - | - | 2.81M | 0.75M |
| Cash | 2.99M | 9.17M | 53.06M | 5.09M | 24.57M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 22.94M | 37.34M | 100.03M | 35.88M | 21.84M |
| Current deferred revenue | - | 1.13M | 0.78M | 0.87M | 0.68M |
| Net debt | 3.92M | 18.12M | 34.88M | 6.58M | -13.87500M |
| Short term debt | 0.95M | 23.61M | 80.77M | 2.54M | 1.77M |
| Short long term debt | - | - | 69.80M | - | - |
| Short long term debt total | 6.92M | 27.30M | 87.95M | 11.67M | 10.70M |
| Other stockholder equity | 764.03M | 728.57M | 677.34M | 599.21M | 553.75M |
| Property plant equipment | - | - | - | 18.03M | 10.32M |
| Total current assets | 45.39M | 39.49M | 140.12M | 157.30M | 272.41M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 172.11M | 337.12M |
| Short term investments | 10.27M | 0.30M | 48.82M | 108.09M | 226.04M |
| Net receivables | 5.20M | 4.77M | 9.66M | 7.02M | 4.93M |
| Long term debt | - | - | - | - | - |
| Inventory | 5.45M | 11.12M | 22.89M | 29.76M | 12.39M |
| Accounts payable | 5.59M | 6.96M | 10.38M | 12.53M | 9.70M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.02M | 0.03M | 0.02M | -1.12400M | -0.53900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.03M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -348.71500M | -216.11900M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.69M | 3.15M | 7.43M | 2.81M | 0.75M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 28.20M | 37.18M | 74.29M | 150.20M | 104.69M |
| Capital lease obligations | 6.92M | 6.93M | 9.61M | 11.67M | 10.70M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -12.74700M | 73.84M | 24.16M | 116.69M | -226.90900M |
| Change to liabilities | - | - | - | 2.31M | 10.74M |
| Total cashflows from investing activities | -12.74700M | 73.84M | 24.16M | 82.77M | -278.06200M |
| Net borrowings | -4.94600M | -48.05800M | 70.95M | -0.03600M | -15.00000M |
| Total cash from financing activities | 24.04M | -13.68500M | 113.81M | 23.01M | 336.11M |
| Change to operating activities | - | - | - | -3.96100M | 1.99M |
| Net income | -26.39500M | -112.01700M | -232.49300M | -132.59600M | -72.43500M |
| Change in cash | -5.06400M | -8.77500M | 12.86M | -19.08000M | -13.87800M |
| Begin period cash flow | 9.57M | 18.35M | 5.49M | 24.57M | 38.45M |
| End period cash flow | 4.51M | 9.57M | 18.35M | 5.49M | 24.57M |
| Total cash from operating activities | -16.34500M | -68.92200M | -125.18100M | -124.81600M | -71.92700M |
| Issuance of capital stock | 31.10M | 44.43M | 57.70M | 23.13M | 342.71M |
| Depreciation | 9.73M | 14.23M | 13.91M | 9.84M | 3.37M |
| Other cashflows from investing activities | - | - | - | -33.13400M | -50.51500M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 4.92M | -0.58700M | -4.15000M | -23.67600M | -15.92800M |
| Change to account receivables | -0.44800M | 4.14M | -2.29600M | -2.90000M | -0.49300M |
| Sale purchase of stock | - | - | - | 22.89M | 351.03M |
| Other cashflows from financing activities | 24.04M | -10.06000M | -14.83500M | -0.08500M | 8.40M |
| Change to netincome | - | - | - | 25.21M | 4.21M |
| Capital expenditures | 0.00000M | 0.10M | 1.69M | 3.30M | 1.46M |
| Change receivables | - | - | - | -2.90000M | -0.49300M |
| Cash flows other operating | - | - | - | -3.42600M | -1.70400M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -19.04200M | -13.87800M |
| Change in working capital | 0.51M | 4.40M | -14.77000M | -28.58800M | -7.65200M |
| Stock based compensation | 4.53M | 9.74M | 15.18M | 22.42M | 9.72M |
| Other non cash items | -4.72900M | 14.73M | 92.99M | 2.35M | 0.85M |
| Free cash flow | -16.34500M | -69.02500M | -126.87200M | -128.11800M | -73.38700M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BNGO Bionano Genomics Inc |
-0.09 7.14% | 1.17 | - | - | 0.49 | 0.33 | 0.08 | -0.1752 |
| ISRG Intuitive Surgical Inc |
3.24 0.77% | 422.06 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOF EssilorLuxottica Société anonyme |
-5.1675 2.52% | 200.15 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-3.16 3.08% | 99.50 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
1.60 1.07% | 151.16 | 25.56 | 12.48 | 2.59 | 1.76 | 2.89 | 12.55 |
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
9540 Towne Centre Drive, San Diego, CA, United States, 92121
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert Erik Holmlin M.B.A., Ph.D. | Pres, CEO, Sec. & Director | 1968 |
| Mr. Mark Oldakowski | Chief Operating Officer | 1974 |
| Mr. Christopher P. Stewart | Chief Financial Officer | 1970 |
| Mr. Mark Adamchak CPA | VP of Accounting & Controller | NA |
| Jonathan Dixon | Global Head of Legal | NA |
| Mr. Stanislas Marin M.B.A., M.S. | Head of Global Sales | NA |
| Ms. Helene Klein | Chief People Officer | NA |
| Dr. Alka Chaubey FACMG, Ph.D. | Chief Medical Officer | 1973 |
| Dr. Soheil Shams Ph.D. | CIO of Emeritus | 1964 |
| Ms. Donna Polizio | Global Head of Market Access | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.